Zenotech Laboratories Ltd Stock Price Today (NSE: ZENOTECH)
Fundamental Score
Zenotech Laboratories Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Zenotech Laboratories Ltd share price today is ₹46.30, up +0.00% on NSE/BSE as of 20 February 2026. Zenotech Laboratories Ltd (ZENOTECH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹294.77 (Cr). The 52-week high for ZENOTECH share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 103.07x, ZENOTECH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.81% and a debt-to-equity ratio of 0.00.
Zenotech Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Zenotech Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Zenotech Laboratories Share Price: A ROCE-Focused Analysis
The pharmaceutical industry, while exhibiting defensive characteristics, faces increasingly stringent regulatory hurdles and pricing pressures globally. Innovation and efficient capital allocation are therefore crucial for sustained value creation. This analysis examines the current trading level of Zenotech Laboratories share price, currently at ₹45.700001, through the lens of Return on Capital Employed (ROCE) efficiency, a key indicator of a company's ability to generate profits from its capital base.
Zenotech Laboratories Ltd displays a ROCE of 9.4%. While positive, this number warrants further investigation when compared to industry benchmarks and peer performance. ROCE is a critical factor in determining a company's ability to reinvest profits, fund future growth, and maintain a competitive advantage. A consistently high ROCE often signals a strong competitive moat, indicating efficient operations and effective capital deployment. A lower ROCE, as observed in Zenotech Laboratories, may suggest inefficiencies or a less robust moat compared to companies with higher ROCE figures.
The company's Price-to-Earnings (PE) ratio currently stands at 103.07. This relatively high PE ratio indicates that investors have high expectations for future earnings growth. However, the ROCE of 9.4% needs to justify this valuation. It's essential to assess whether the company's strategic initiatives and operational improvements are likely to drive ROCE upwards to levels commensurate with the current market expectations reflected in the share price.
Furthermore, a qualitative assessment is essential. For example, when compared to peers like
Mankind Pharma Ltd, factors like the perceived quality of management, their track record in innovation, and their ability to navigate regulatory complexities play a crucial role in investor confidence. While Mankind Pharma Ltd. may command a premium due to perceived stronger management, Zenotech Laboratories Ltd. needs to demonstrate tangible improvements in efficiency and strategic execution to bridge the valuation gap. The long-term sustainability of Zenotech Laboratories share price will depend on its ability to improve its ROCE and align it with investor expectations and peer performance. This analysis is part of a comprehensive 80-parameter fundamental audit verified by Sweta Mishra.Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zenotech Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZENOTECH across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (41.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹44.25 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (4.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.40%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 103.07x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-224.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (0.36% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.36% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zenotech Laboratories Ltd Financial Statements
Comprehensive financial data for Zenotech Laboratories Ltd including income statement, balance sheet and cash flow
About ZENOTECH (Zenotech Laboratories Ltd)
Zenotech Laboratories Ltd (ZENOTECH) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹294.77 (Cr). Zenotech Laboratories Ltd has delivered a Return on Equity (ROE) of 4.81% and a ROCE of 9.40%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking ZENOTECH share price can monitor key metrics including P/E ratio, promoter holding of 68.84%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
ZENOTECH Share Price: Frequently Asked Questions
What is the current share price of Zenotech Laboratories Ltd (ZENOTECH)?
As of 20 Feb 2026, 06:31 am IST, Zenotech Laboratories Ltd share price is ₹46.30. The ZENOTECH stock has a market capitalisation of ₹294.77 (Cr) on NSE/BSE.
Is ZENOTECH share price Overvalued or Undervalued?
ZENOTECH share price is currently trading at a P/E ratio of 103.07x, compared to the industry average of 31.77x. Based on this relative valuation, the Zenotech Laboratories Ltd stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of ZENOTECH share price?
The 52-week high of ZENOTECH share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Zenotech Laboratories Ltd share price?
Key factors influencing ZENOTECH share price include quarterly earnings growth (Sales Growth: 14.94%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Zenotech Laboratories Ltd a good stock for long-term investment?
Zenotech Laboratories Ltd shows a 5-year Profit Growth of 0.36% and an ROE of 4.81%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in ZENOTECH shares.
How does Zenotech Laboratories Ltd compare with its industry peers?
Zenotech Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare ZENOTECH share price P/E of 103.07x and ROE of 4.81% against the industry averages to determine competitive standing.
What is the P/E ratio of ZENOTECH and what does it mean?
ZENOTECH share price has a P/E ratio of 103.07x compared to the industry average of 31.77x. Investors pay ₹103 for every ₹1 of annual earnings.
How is ZENOTECH performing according to Bull Run's analysis?
ZENOTECH has a Bull Run fundamental score of 34/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ZENOTECH belong to?
ZENOTECH operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Zenotech Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for ZENOTECH?
ZENOTECH has an ROE of 4.81%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Zenotech Laboratories Ltd generates profits from shareholders capital.
How is ZENOTECH debt-to-equity ratio and what does it indicate?
ZENOTECH has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is ZENOTECH dividend yield and is it a good dividend stock?
ZENOTECH offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Zenotech Laboratories Ltd shares.
How has ZENOTECH share price grown over the past 5 years?
ZENOTECH has achieved 5-year growth rates of: Sales Growth 10.59%, Profit Growth 0.36%, and EPS Growth 0.36%.
What is the promoter holding in ZENOTECH and why does it matter?
Promoters hold 68.84% of ZENOTECH shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Zenotech Laboratories Ltd.
What is ZENOTECH market capitalisation category?
ZENOTECH has a market capitalisation of ₹295 crores, placing it in the Small-cap category.
How volatile is ZENOTECH stock?
ZENOTECH has a beta of N/A. A beta > 1 suggests the Zenotech Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ZENOTECH operating profit margin trend?
ZENOTECH has a 5-year average Operating Profit Margin (OPM) of 41.01%, indicating the company's operational efficiency.
How is ZENOTECH quarterly performance?
Recent quarterly performance shows Zenotech Laboratories Ltd YoY Sales Growth of 14.94% and YoY Profit Growth of -224.14%.
What is the institutional holding pattern in ZENOTECH?
ZENOTECH has FII holding of 0.00% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the Zenotech Laboratories Ltd stock.